Anti-α-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event

por Freedman, MS, Laks, J, Dotan, N, Altstock, RT, Dukler, A, Sindic, CJM
Publicado 2009

Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents

por Kang, H., Hii, M., Le, M., Tam, R., Riddehough, A., Traboulsee, A., Kolind, S., Freedman, M.S., Li, D.K.B.
Publicado en AJNR Am J Neuroradiol (2018)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis

por Freedman, MS, Wolinsky, JS, Truffinet, P, Comi, G, Kappos, L, Miller, AE, Olsson, TP, Benamor, M, Chambers, S, O’Connor, PW
Publicado en Mult Scler J Exp Transl Clin (2015)

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper

por Saccardi, R, Freedman, MS, Sormani, MP, Atkins, H, Farge, D, Griffith, LM, Kraft, G, Mancardi, GL, Nash, R, Pasquini, M, Martin, R, Muraro, PA
Publicado 2012

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis

por Das, J, Snowden, JA, Burman, J, Freedman, MS, Atkins, H, Bowman, M, Burt, RK, Saccardi, R, Innocenti, C, Mistry, S, Laud, PJ, Jessop, H, Sharrack, B
Publicado en Mult Scler (2021)

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

por Freedman, MS, Metzig, C, Kappos, L, Polman, CH, Edan, G, Hartung, H-P, Miller, DH, Montalban, X, Yarden, J, Spector, L, Fire, E, Dotan, N, Schwenke, S, Lanius, V, Sandbrink, R, Pohl, C
Publicado 2012

Differential diagnosis of suspected multiple sclerosis: a consensus approach

por Miller, DH, Weinshenker, BG, Filippi, M, Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, M, Johnson, RT, Kappos, L, Kira, J, Lublin, FD, McFarland, HF, Montalban, X, Panitch, H, Richert, JR, Reingold, SC, Polman, CH
Publicado 2008

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis

por Hartung, H-P, Berger, T, Bermel, RA, Brochet, B, Carroll, WM, Holmøy, T, Karabudak, R, Killestein, J, Nos, C, Patti, F, Ross, A Perrin, Vanopdenbosch, L, Vollmer, T, Buffels, R, Garas, M, Kadner, K, Manfrini, M, Wang, Q, Freedman, MS
Publicado en Mult Scler Relat Disord (2020)